“And so we anticipate further growth, anticipated four launches of Mounjaro outside of the U.S. and continue with that throughout the year as well as into 2025.”

In context

“amp in '24 but also into 2025? Joe Fletcher: Thanks, Terence, for the question. I'll hand over to Ilya Yuffa, President of Lilly International for that question. Ilya Yuffa: Thanks, Terence. As we think about Mounjaro launches outside the U.S., we have already launched in a number of select markets. We have foundation to be competitive in many of our markets, and we anticipate continued launches. We've just launched in vial format in select markets outside of the U.S., mainly in Australia, Canada and Germany, and Poland. And we just received QuickPen approval in the U.K., and so we're anticipating launch there. As we get additional regulatory approvals for a multi-use QuickPen and we monitor our ramp-up in capacity for supply, we'll continue to launch in other markets throughout the year. And so we anticipate further growth, anticipated four launches of Mounjaro outside of the U.S. and continue with that throughout the year as well as into 2025. Operator: The next question is coming from Chris Schott from JPMorgan. Chris, your line is live. Christopher Schott: All right, great. Thanks so much. On Zepbound, seems like you're making strong progress on coverage but just interested in expectations for the remainder of this year as we think about just where coverage could go and just how to think about ASP. I guess the core question is, is it reasonable to think that most payers who cover will add Zepbound year? Joe Fletcher: Thanks, Chris. I'll hand over to Patrik to comment on that question about Zepbound coverage. Patrik Jonsson: Yes. Thank you very much, Chris. As we stated, we are pleased we are so early in launch with the 35% commercial access, having contract a and Our efforts moving forward will really be to continue to expand”